SELLAS (SLS) stock jumps about 10% in premarket as REGAL AML trial milestone stays in focus
SELLAS Life Sciences shares jumped about 10% to $4.14 in premarket U.S. trading Friday, after a 13.9% gain in the previous session. Investors are watching for the final analysis trigger in the company’s late-stage REGAL study in acute myeloid leukemia, which has not yet been reached.